Partial Response Reported With Abemaciclib for Breast Cancer Metastases to Brain

Modesto Morganelli
Dicembre 7, 2017

"Observations suggest that the PD-1/PD-L1 pathway plays an important role in the trastuzumab resistance that we see in patients with metastatic HER2-positive breast cancer, and the PANACEA study provides proof-of principle evidence that PD-1 inhibition like pembrolizumab can help reverse this", added Loi.

"About 15% of breast cancers are HER2-positive, but another 45% have low levels of HER2, and these patients are not now treated with adjuvant trastuzumab", said Louis Fehrenbacher, MD, of the Kaiser Permanente Vallejo Medical Center in California, according to a press release. Data from early trastuzumab trials showed that those HER2-low patients derived similar benefit from the agent as HER2-positive patients, so the researchers conducted a large randomized trial to test this possibility. These results were presented at the 2017 San Antonio Breast Cancer Symposium (SABCS 2017). "There is a clear need to develop new therapeutic approaches for patients presenting with HER2-positive metastatic breast cancer that has become resistant to trastuzumab". Grade 3/4 neutropenia was reported in 61 percent of patients in the ribociclib arm compared with 4 percent in the placebo arm, but it was asymptomatic in most patients; neutropenia associated with fever and infection was reported in 2 percent of patients in the ribociclib arm and 1 percent in the placebo arm.

The study had a median follow-up of 46.1 months, during which time 264 patients had a recurrence, diagnosis of a new breast cancer, diagnosis of a new cancer outside the breast, or died.

COHORT 2: Patients receive trastuzumab IV over 90 minutes on day 0 of course 1 and day 1 of subsequent courses, and utomilumab IV over 1 hour on day 1.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE